AGRX - アジャイル・セラピュ―ティクス (Agile Therapeutics Inc.) アジャイル・セラピュ―ティクス

 AGRXのチャート


 AGRXの企業情報

symbol AGRx
会社名 Agile Therapeutics Inc (アジャイル・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アジャイル・セラピューティクス(Agile Therapeutics Inc.)は女性の健康向けスペシャリティ医薬品企業。同社は、新規処方避妊製品の開発と商業化に焦点を当てる。同社の製品候補は、利便性を提供し、コンプライアンスを促進する避妊オプションを女性に提供するために設計される。同社のリード製品候補の「Twirla」はまた「AG200-15」として知られ、フェーズⅢ臨床開発にある週一回の処方避妊パッチである。「Twirla」は、利用可能なパッチを上回る利点を提供するように設計され、パッチの密着性・安定性と患者の快適性を最適化するように意図される「Skinfusion」という経皮パッチ技術に基づく。「Twirla」は、プロゲスチンの一種の合成ステロイドホルモンであるレボノルゲストレル(LNG)、及び合成エストロゲンである有効成分のエチニルエストラジオール(EE)を含有する複合ホルモン避妊薬(CHC)パッチである。   アジャイル・セラピュ―ティクスは、女性のヘルスケア製品に特化した米国の医薬品開発会社。新規処方避妊製品の開発と商業化に注力する。避妊用の経皮パッチ技術「スキンフュ―ジョン」を研究・開発する。同社の製品候補である避妊パッチ「Twirla(別名AG200-15)」は、避妊を選択する女性に利便性を提供し、迎合性を容易にする。  Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
本社所在地 101 Poor Farm Road Princeton NJ 08540 USA
代表者氏名 Alfred Altomari アルフレッドアルトマリ
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 609-683-1880
設立年月日 35765
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数
url www.agiletherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/agrx
adr_tso
EBITDA EBITDA(百万ドル) -24.44100
終値(lastsale) 0.46
時価総額(marketcap) 15813571.34
時価総額 時価総額(百万ドル) 24.40790
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 9.46790
当期純利益 当期純利益(百万ドル) -25.51900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Agile Therapeutics Inc revenues was not reported. Net loss decreased 19% to $12.2M. Lower net loss reflects Other Research and Development decrease of 28% to $5.7M (expense) Other General and administrative decrease of 10% to $4M (expense) Interest expense decrease of 34% to $688K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.52 to -$0.36.

 AGRXのテクニカル分析


 AGRXのニュース

   Is the Options Market Predicting a Spike in Agile Therapeutics (AGRX) Stock?  2020/05/07 12:36:00 Zacks Investment Research
Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.
   Agile Therapeutics Reports First Quarter 2020 Financial Results  2020/05/05 20:01:00 GlobeNewswire
FDA Approved Twirla® Expected to Reach Wholesalers in the Fourth Quarter of 2020 $93.9 Million in Cash and Cash Equivalents as of March 31, 2020 …
   The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace  2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
   Is Agile Therapeutics (AGRX) Stock Outpacing Its Medical Peers This Year?  2020/02/21 16:30:10 Zacks Investment Research
Is (AGRX) Outperforming Other Medical Stocks This Year?
   Agile Therapeutics EPS misses by $0.02  2020/02/20 21:25:11 Seeking Alpha
Agile Therapeutics (NASDAQ:AGRX): Q4 GAAP EPS of -$0.10 misses by $0.02. Cash and equivalents of $34.5M. Shares -14.3%. Press Release
   Is the Options Market Predicting a Spike in Agile Therapeutics (AGRX) Stock?  2020/05/07 12:36:00 Zacks Investment Research
Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.
   Agile Therapeutics Reports First Quarter 2020 Financial Results  2020/05/05 20:01:00 GlobeNewswire
FDA Approved Twirla® Expected to Reach Wholesalers in the Fourth Quarter of 2020 $93.9 Million in Cash and Cash Equivalents as of March 31, 2020 …
   The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace  2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
   Is Agile Therapeutics (AGRX) Stock Outpacing Its Medical Peers This Year?  2020/02/21 16:30:10 Zacks Investment Research
Is (AGRX) Outperforming Other Medical Stocks This Year?
   Agile Therapeutics EPS misses by $0.02  2020/02/20 21:25:11 Seeking Alpha
Agile Therapeutics (NASDAQ:AGRX): Q4 GAAP EPS of -$0.10 misses by $0.02. Cash and equivalents of $34.5M. Shares -14.3%. Press Release
   Is the Options Market Predicting a Spike in Agile Therapeutics (AGRX) Stock?  2020/05/07 12:36:00 Zacks Investment Research
Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.
   Agile Therapeutics Reports First Quarter 2020 Financial Results  2020/05/05 20:01:00 GlobeNewswire
FDA Approved Twirla® Expected to Reach Wholesalers in the Fourth Quarter of 2020 $93.9 Million in Cash and Cash Equivalents as of March 31, 2020 …
   The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace  2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
   Is Agile Therapeutics (AGRX) Stock Outpacing Its Medical Peers This Year?  2020/02/21 16:30:10 Zacks Investment Research
Is (AGRX) Outperforming Other Medical Stocks This Year?
   Agile Therapeutics EPS misses by $0.02  2020/02/20 21:25:11 Seeking Alpha
Agile Therapeutics (NASDAQ:AGRX): Q4 GAAP EPS of -$0.10 misses by $0.02. Cash and equivalents of $34.5M. Shares -14.3%. Press Release

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アジャイル・セラピュ―ティクス AGRX Agile Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)